From courtroom to clinic: Pavblu's first year in review

Market Event Summary

Carolina Ruivo, Ph.D. | October 2025

Pavblu turns 1: uptake and what's next

A legal victory turned into commercial success

Amgen's Pavblu entered the U.S. market on October 28, 2024, after the Federal Circuit rejected Regeneron's injunction request to block its launch. One year later, it remains the sole biosimilar alternative to Eylea, the historical standard of care for treating wet AMD and DME.

- Pavblu has gained remarkable traction, with QoQ sales growing rapidly, from $31 million in the final nine weeks of 2024 to $126 million in Q2 2025.
- Regeneron's blockbuster drug Eylea experienced a notable decline in U.S. net sales, from $1.19 billion in Q4 2024 to $754 billion in Q2 2025.



U.S. net sales of Pavblu ($M)

The coming wave of Eylea biosimilars

While several Eylea biosimilars have secured FDA approval, patent disputes and injunctions have delayed their launch, granting Pavblu an exclusivity window initially projected through June 2027. This advantage has enabled Pavblu to dominate the retinal segment without direct competition. However, recent settlements with Regeneron are accelerating biosimilar entry, signaling earlier-than-expected market pressure.

- Biocon took the lead in April 2025, paving the way for Yesafili's launch in H2 2026. Sandoz followed in September, securing Enzeevu's commercialization by year-end 2026. In October, Formycon cleared the path for Ahzantive in Q4 2026, while Celltrion locked in Eydenzelt's debut for December 31, 2026. These agreements significantly shorten Pavblu's exclusivity period, heightening competitive intensity from late 2026 onward.

Clarivate's takeaways

Strong adoption is driving market share

Pavblu gained rapid traction as the first Eylea biosimilar, supported by its availability in a PFS, a feature clinicians highly value for convenience and efficiency. Physicians view Pavblu as clinically equivalent to Eylea, and its permanent Q-code ensures seamless reimbursement. In fact, Clarivate's PMR indicates that Pavblu's growth is driven primarily by share shift from Eylea, underscoring strong confidence in its performance and signaling a path for continued market penetration.

First-to-market advantage creates a durable lead

By the time competing Eylea biosimilars enter the U.S. market in late 2026, Pavblu will have two years of real-world clinical data, strengthening physicians' confidence and positioning it as the preferred option. Interviewed KOLs note that some payers are already imposing step therapy protocols for biosimilars, a trend that will likely accelerate Pavblu's adoption in wet AMD and DME.

Competitive landscape and market dynamics

While Pavblu benefits from exclusivity, competitive pressures are mounting. Avastin remains a cost-effective option, while Vabysmo and Eylea HD allow extended dosing intervals, a compelling value proposition for providers and patients. These dynamics highlight the need for Pavblu to capitalize on its early adoption, payer-driven advantages, and robust real-world evidence to sustain its lead as the market evolves.

About the author

Carolina Ruivo, Ph.D.

Senior Healthcare Research & Data Analyst

DRG Commercial Solutions

Dr. Ruivo's focus is the ophthalmology market. Previously, she was a content specialist in Cortellis, the suite of life science intelligence solutions from Clarivate. She holds a Ph.D. in biomedical sciences from Pompeu Fabra University in Barcelona, Spain, and a B.S. in biology from the University of Aveiro in Portugal.

Clarivate coverage of wet AMD products

- Disease Landscape & Forecast | Dry and Wet Age-Related Macular Degeneration (G7) (published in 2025)
- Current Treatment: Physician Insights | Dry and Wet Age-Related Macular Degeneration (US) (published in 2024)
- Treatment Algorithms: Claims Data Analysis | Wet Age-Related Macular Degeneration (US) (published in 2025)
- Access & Reimbursement | Age-Related Macular Degeneration (US) (published in 2024)
- Unmet Need | Wet Age-Related Macular Degeneration (US/EU) (published in 2023)

Clarivate coverage of DME products

- Disease Landscape & Forecast | Diabetic Macular Edema / Diabetic Retinopathy (G7) (published in 2025)
- Treatment Algorithms: Claims Data Analysis | Diabetic Macular Edema (US) (published in 2025)
- Current Treatment: Physician Insights | Diabetic Macular Edema / Diabetic Retinopathy (US) (published in 2024)



About Clarivate

Clarivate is the leading global information services provider. We connect people and organizations to intelligence they can trust to transform their perspective, their work and our world. Our subscription and technology-based solutions are coupled with deep domain expertise and cover the areas of Academia & Government, Life Sciences & Healthcare and Intellectual Property. For more information, please visit clarivate.com